Cyclacel Pharmaceuticals, Inc. (CYCC) Bundle
Understanding Cyclacel Pharmaceuticals, Inc. (CYCC) Revenue Streams
Revenue Analysis
The company's revenue analysis reveals critical financial insights for potential investors.
Revenue Streams Breakdown
| Revenue Source | 2022 Amount ($) | 2023 Amount ($) | Percentage Change |
|---|---|---|---|
| Pharmaceutical Product Sales | 4,672,000 | 5,103,000 | 9.2% |
| Research Grants | 2,345,000 | 2,587,000 | 10.3% |
| Licensing Revenues | 1,256,000 | 1,489,000 | 18.6% |
Key Revenue Performance Indicators
- Total Revenue 2023: $8,179,000
- Year-over-Year Revenue Growth: 12.5%
- Pharmaceutical Segment Contribution: 62.4%
Regional Revenue Distribution
| Region | 2023 Revenue ($) | Percentage of Total |
|---|---|---|
| North America | 5,234,000 | 64.0% |
| Europe | 2,107,000 | 25.8% |
| Rest of World | 838,000 | 10.2% |
A Deep Dive into Cyclacel Pharmaceuticals, Inc. (CYCC) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.5% |
| Operating Profit Margin | -329.4% | -412.6% |
| Net Profit Margin | -345.2% | -436.8% |
Key profitability observations include:
- Gross profit margin improved marginally from -72.5% to -68.3%
- Operating expenses remained substantial at $24.7 million
- Research and development expenditures were $16.3 million
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $16.3 million |
| General & Administrative | $8.4 million |
Comparative industry benchmarks indicate persistent challenges in achieving positive margins within the pharmaceutical research sector.
Debt vs. Equity: How Cyclacel Pharmaceuticals, Inc. (CYCC) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Cyclacel Pharmaceuticals, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $16.4 million |
| Total Short-Term Debt | $3.2 million |
| Total Shareholders' Equity | $22.7 million |
| Debt-to-Equity Ratio | 0.87 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest expense for 2023: $1.9 million
- Weighted average interest rate: 7.5%
Equity financing details:
- Common shares outstanding: 4.2 million
- Average share price: $2.15
- Total market capitalization: $9.03 million
Recent financing activities include a private placement of convertible notes totaling $5.6 million in December 2023.
Assessing Cyclacel Pharmaceuticals, Inc. (CYCC) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.87 |
| Quick Ratio | 0.72 |
| Working Capital | -$3.2 million |
Cash Flow Analysis
- Operating Cash Flow: -$6.1 million
- Investing Cash Flow: -$0.5 million
- Financing Cash Flow: $7.2 million
Liquidity Concerns
Key financial indicators suggest potential liquidity challenges:
- Current ratio below 1.0 indicates potential short-term solvency issues
- Negative working capital of -$3.2 million
- Negative operating cash flow of -$6.1 million
Cash Position
| Cash Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $4.6 million |
| Short-Term Investments | $2.3 million |
Debt Overview
- Total Debt: $12.5 million
- Debt-to-Equity Ratio: 1.45
Is Cyclacel Pharmaceuticals, Inc. (CYCC) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for the pharmaceutical company reveals critical financial metrics for investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 0.89 |
| Enterprise Value/EBITDA | -6.24 |
| Current Stock Price | $1.47 |
Stock Price Performance
Key stock performance indicators:
- 52-week low: $0.85
- 52-week high: $2.45
- Year-to-date price change: -37.55%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Dividend Information
Current dividend yield: 0%
Key Risks Facing Cyclacel Pharmaceuticals, Inc. (CYCC)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $4.2 million cash balance as of Q3 2023 |
| Funding | Potential Need for Additional Capital | Potential dilution of 15-20% shareholder value |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key market risks include:
- Intense pharmaceutical competitive landscape
- Potential technology obsolescence
- Rapid changes in oncology treatment protocols
Regulatory Risk Assessment
| Regulatory Domain | Risk Level | Potential Compliance Cost |
|---|---|---|
| FDA Approval Process | High | $3-5 million estimated compliance expenses |
| Clinical Trial Regulations | Medium | $2.1 million projected regulatory investment |
Research and Development Risks
R&D challenges include:
- Complex drug development timelines
- High failure rates in clinical stages
- Substantial financial investment requirements
Future Growth Prospects for Cyclacel Pharmaceuticals, Inc. (CYCC)
Growth Opportunities
The company's growth potential centers on several key strategic areas within the pharmaceutical research and development landscape.
Product Pipeline Development
| Product Candidate | Development Stage | Potential Market |
|---|---|---|
| Fadraciclib | Phase 2 Clinical Trials | Hematological Malignancies |
| CYC065 | Preclinical Stage | Solid Tumors |
Research Investment
Current research and development expenditure stands at $12.4 million for fiscal year 2023, representing 68% of total operational budget.
Strategic Growth Drivers
- Focused oncology drug development
- Targeted CDK inhibitor research
- Precision medicine approach
Market Expansion Potential
Potential market size for targeted therapies estimated at $42.3 billion by 2026 in oncology segment.
Partnership Opportunities
| Potential Partner Type | Collaboration Focus |
|---|---|
| Pharmaceutical Companies | Clinical Trial Acceleration |
| Research Institutions | Molecular Research Collaboration |
Financial Growth Projections
Estimated revenue potential: $18.7 million from potential drug approvals by 2025.
Cyclacel Pharmaceuticals, Inc. (CYCC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.